Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025431) TREATMENT OF LOCAL SKIN HYPOTROPHY CONDITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025431 International Application No.: PCT/EP2018/070712
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
A61K 38/18 (2006.01) ,A61P 17/00 (2006.01) ,A61P 17/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
02
for treating wounds, ulcers, burns, scars, keloids, or the like
Applicants:
ACCANIS BIOTECH F&E GMBH & CO KG [AT/AT]; Karl-Farkas-Gasse 22 1030 Vienna, AT
Inventors:
MANDLER, Markus; AT
MATTNER, Frank; AT
SCHMIDT, Walter; AT
SCHNEEBERGER, Achim; AT
Agent:
SONN & PARTNER PATENTANWÄLTE; Riemergasse 14 1010 Vienna, AT
Priority Data:
17183990.531.07.2017EP
Title (EN) TREATMENT OF LOCAL SKIN HYPOTROPHY CONDITIONS
(FR) TRAITEMENT D'ÉTATS HYPOTROPHIQUES CUTANÉS LOCAUX
Abstract:
(EN) The invention discloses Fibroblast growth factor 2 (FGF2) and Fibroblast growth factor 7 (FGF7) messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' untranslated region (5'-UTR), a coding region, a 3' untranslated region (3'-UTR) and a poly-adenosine tail (poly-A tail), for use in the treatment of local skin hypotrophy conditions and kits for administrating this mRNA to a human patient in need thereof.
(FR) La présente invention concerne un ARN messager (ARNm) du facteur de croissance 2 des fibroblastes (FGF2) et du facteur de croissance 7 des fibroblastes (FGF7) , lequel ARNm comporte une région CAP 5', une région non traduite 5', une région codante, une région non traduite 3' (3'UTR) et une queue poly-adénosine (queue poly-A), cet ARNm étant destiné à être utilisé dans le traitement de conditions hypotrophiques cutanées locales; cette invention porte également sur des trousses pour administrer cet ARNm à un patient humain nécessitant un tel traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)